openPR Logo
Press release

Pharmacogenomics Market to Demonstrate Immense Growth Potential at 5.8% of CAGR by 2023

12-19-2017 06:02 PM CET | Business, Economy, Finances, Banking & Insurance

Press release from: Market Research Future

Pharmacogenomics Market

Pharmacogenomics Market

Pharmacogenomics defines how genes can affect a person’s response to drugs. It is relatively a new field and combines pharmacology and genomics. The aim of Pharmacogenomics Market is to develop effective and safe medications. Moreover by pharmacogenomics, drugs doses can be tailored to a person’s genetic makeup. The field of pharmacogenomics is predicted to treat a wide range of health problems including cardiovascular diseases, Alzheimer disease, cancer, HIV/AIDS, and asthma, in near future. The Global Pharmacogenomics Market is expected to grow at a ~CAGR of 5.8% during the forecast period.

Get a Sample Report @ https://www.marketresearchfuture.com/sample_request/1177 .

Pharmacogenomics is the study of how genes effect on a person’s response to drugs. This comparatively latest theory combines pharmacology (the science of drugs) and genomics (the study of genes and their functions) to advance effective, safe medications and doses that will be tailored to a person’s genetic condition.

Some of the factors driving the market are increasing prevalence of several infectious and non-infectious diseases, rising use of drug discovery processes, increasing demand for personalized drugs, and developing awareness about benefits related with pharmacogenomics. Illnesses needs proper effective treatment that should be more reliable and safe at the same time. Pharmacogenomics can help to achieve both. Increasing awareness about its benefits is likely to drive demand globally.

Application of pharmacogenomics would seriously benefit physicians in the treatment of a particular segment of population by studying their responses to specific drugs. Additionally, the knowledge of effectiveness of a drug in a patient would make a drug more reliable, and limit the number of drugs to be withdrawn from the market due to different negative reactions in some patients to whom they were reacted.

Competitive Analysis:

The key players for the global pharmacogenomics market are Myriad Genetics, Inc. (U.S.), 23andMe, Inc. (U.S.), Pathway Genomics (U.S.), GeneTech (U.S.), GeneDx. (U.S.), Future Science Group (U.S.), Teva Pharmaceutical Industries Ltd. (Israel), Assurex Health, Inc. (U.S.), and others.

Regional Analysis:

The Americas dominate the global pharmacogenomics market owing to a well-developed healthcare sector and presence of developed economies like the U.S. and Canada. Moreover, increasing number of patients suffering from cardiovascular diseases and rising healthcare expenditure have boosted the growth of the market in America. In 2016, according to the Centres for Diseases Control and Prevention in the U.S., heart disease was the leading cause of death for both men and women. Moreover, it was also estimated that the healthcare expenditure for heart diseases in the U.S. reaches USD 200 billion each year.

Europe is the second largest Pharmacogenomics Industry, followed by Asia Pacific. Availability of funds for research and development along with government support and presence of huge patient population within the region will drive the market growth during the forecast period. Moreover, the presence of the developed economies like Germany and France within the region fuels the market growth.

Order Single User License Copy of 90 Premium Pages is Available @ https://www.marketresearchfuture.com/reports/pharmacogenomics-market-1177 .

Asia Pacific is the fastest growing region for the market due to the presence of a huge patient population, continuously developing economies like India and China and presence of huge opportunities in the market drives the market. According to the Indian Brand Equity Foundation in 2016, the Indian biotech industry is estimated to reach USD 100 billion by 2025 from USD 7 billion in 2015 with a CAGR of 30.46%.

On the other hand, the Middle East & Africa has the least share in the global pharmacogenomics market due to presence of poor economy, low per capita healthcare expenditure and stringent government policies especially in the Africa region. The majority of the market of this region is held by the Middle East due to a well-developed healthcare sector and huge healthcare expenditure. Moreover, developed economies like Dubai, Saudi Arabia, Dubai, besides others fuels the market growth within the Middle East & Africa region.

Brief TOC

Report Prologue
Market Introduction
Research Methodology
Market Dynamics
Market Factor Analysis
Global Pharmacogenomics Market, By Application
Global Pharmacogenomics Market, By Therapeutic Application
Global Pharmacogenomics Market, By Methods
Global Pharmacogenomics Market, By Region
Company Profile
Conclusion
Appendix

Ask to Expert @ https://www.marketresearchfuture.com/enquiry/1177 .

About US:

Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

Contact:
Akash Anand,
Market Research Future
+1 646 845 9312
Email: sales@marketresearchfuture.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Pharmacogenomics Market to Demonstrate Immense Growth Potential at 5.8% of CAGR by 2023 here

News-ID: 868456 • Views:

More Releases from Market Research Future

Cerebral Palsy Industry Projected to Reach USD 4.036 billion by 2035 with Steady Long-Term Growth
Cerebral Palsy Industry Projected to Reach USD 4.036 billion by 2035 with Steady …
The global healthcare sector continues to place increasing emphasis on neurological disorders that require long-term management and multidisciplinary care. Among these, cerebral palsy remains one of the most common childhood motor disabilities, affecting movement, posture, and muscle coordination. As awareness grows and treatment options continue to advance, the cerebral palsy industry is witnessing steady expansion driven by improved diagnosis, therapeutic innovation, and rising investments in rehabilitation services. According to Market Research
Reclaimed Lumber Market revenue expected to rise from USD 53.47 Billion in 2024 to USD 85.52 Billion by 2035
Reclaimed Lumber Market revenue expected to rise from USD 53.47 Billion in 2024 …
Based on the market research report from Market Research Future, here is a detailed overview of the global reclaimed lumber market. This sector is thriving at the intersection of environmental sustainability and distinctive design. What is Reclaimed Lumber? Reclaimed lumber is wood sourced from old structures like barns, factories, warehouses, and wine barrels, which is then processed and remilled for new use. It offers a unique combination of environmental benefits-reducing deforestation and
Cardiovascular Information Systems Industry Expected to Reach USD 1,330.86 million by 2035 with Steady Growth Momentum
Cardiovascular Information Systems Industry Expected to Reach USD 1,330.86 milli …
The global healthcare sector is undergoing a rapid digital transformation, particularly in specialized areas such as cardiovascular care where data accuracy, workflow efficiency, and real-time monitoring are critical. Cardiovascular Information Systems (CVIS) have emerged as essential platforms that integrate imaging, patient records, diagnostic data, and clinical workflows to support comprehensive cardiac care management. According to Market Research Future (MRFR), the Cardiovascular Information System Market was valued at USD 640.0 million in
Low E-Glass Industry forecast highlights robust 6.5% CAGR growth through 2035
Low E-Glass Industry forecast highlights robust 6.5% CAGR growth through 2035
Low-emissivity (Low-E) glass has a microscopically thin, transparent coating that reflects infrared energy (heat) while allowing visible light to pass through. This principle helps keep buildings warm in the winter by reflecting interior heat back inside, and cool in the summer by blocking exterior heat, all while reducing harmful UV rays. The Global Low-E Glass Market: An Overview The global Low-E glass market is on a strong growth trajectory, driven by the

All 5 Releases


More Releases for Pharmacogenomics

Pharmacogenomics - Top Companies Regional and Data Analysis
Pharmacogenomics is a branch of science, which studies the role of gene over the activity of a drugs and hence helps the refreshers in predicting the response of novel as well as previously available therapies. Get More Details with Sample PDF Copy @ https://www.theinsightpartners.com/sample/TIPRE00007564/?utm_source=OpenPR&utm_medium=10129 Major Companies operating in the Pharmacogenomics Market are: • F. Hoffmann-la Roche Ltd • Abbott • Oxford Nanopore Technologies • Thermo Fisher Scientific Inc. • Illumina, Inc. • QIAGEN • Agilent Technologies, Inc. • Myriad Genetics, Inc. • Admera Health Contact Us: If you have any queries about
Pharmacogenomics Market worth $5.8 billion by 2028
North America region is witnessing increasing investments and research activities in the field of drug discovery and development. The need for advanced therapies due to rising rate of cancer has contributed to growth of the pharmacogenomics market. Pharmacogenomics Market [https://www.marketsandmarkets.com/Market-Reports/pharmacogenomics-market-142682251.html?utm_source=ABnewswire&utm_campaign=Paid&utm_content=Referral] in terms of revenue was estimated to be worth $3.5 billion in 2023 and is poised to reach $5.8 billion by 2028, growing at a CAGR of 10.6% from 2023 to
Genetic Medicine: Unveiling the Power of Pharmacogenomics
Based on technology, the pharmacogenomics market is segmented into PCR, sequencing, microarray, gel electrophoresis, mass spectrometry, and others. The market for the PCR segment is subsegmented into real time PCR, standard PCR, and digital PCR. The PCR segment dominated the pharmacogenomics market in 2021 and is expected to register the highest CAGR during the forecast period. Download Sample PDF Details at: https://www.theinsightpartners.com/sample/TIPRE00007564?utm_source=OpenPR&utm_medium=10776 The pharmacogenomics market is segmented on the basis of
Complete PDF Guide On Pharmacogenomics [PDF]
According to our latest study on "Pharmacogenoics Market Forecast to 2028 - COVID-19 Impact and Global Analysis - by Technology, Application, and End User," the market is projected to reach US$ 14,107.80 million by 2028 from US$ 7,087.81 million in 2021; it is expected to grow at a CAGR of 10.3% from 2021 to 2028. The report highlights the key factors driving the market growth and prominent players with their
Global Pharmacogenomics Market Size & Trends
According to a new market research report published by Global Market Estimates, the global pharmacogenomics market is projected to grow at a CAGR of 9.6% from 2023 to 2028. The growth of the global pharmacogenomics market is driven by advancements in genomics and DNA sequencing technologies, the rising demand for personalized medicine, regulatory support from agencies like the FDA, cost-effectiveness through reduced adverse reactions, and a growing aging population with complex
Global Pharmacogenomics Services Market Insights | 2022-2032
The Pharmacogenomics Services Market refers to the services provided by companies and laboratories that offer personalized medicine based on a patient's genetic makeup. Pharmacogenomics is the study of how an individual's genes affect their response to certain drugs, and the pharmacogenomics services market focuses on utilizing this knowledge to optimize drug therapy. These services typically involve genetic testing to identify specific genetic variations that may impact a patient's response to certain